Form 990 for tax year 2024

Totals

Total revenue

$358,698,504

Total expenses

$398,128,476

Contributions and grants received

$315,334,371

Grants paid

$124,083,834

Program service revenue

$16,079,272

Investment income

$22,273,771

Other revenue

$5,011,090

Total assets, end of year

$532,209,663

Total liabilities, end of year

$171,712,720

Net assets or fund balances, end of year

$360,496,943

Program services expenses (Part IX)

$295,802,037

Management and general expenses

$52,573,915

Fundraising expenses

$49,752,524

Program service expenses (Part III)

$295,802,037

Program services were 74.3% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Mission and programs · 2024

• A) RESEARCH PROGRAMS:AT BLOOD CANCER UNITED, WE ARE PUSHING BOUNDARIES TOWARD POWERFUL NEW THERAPIES. WE PROPEL GROUNDBREAKING CANCER TREATMENTS THROUGH ALL PHASES OF THE RESEARCH AND DRUG DEVELOPMENT PROCESS AND ARE PROUD THAT OUR SUPPORT HAS BEEN KEY TO ADVANCING 80% OF THE 153 BLOOD CANCER TREATMENT APPROVALS SINCE 2017.AS WE CONTINUED TO SUPPORT THE SEARCH FOR LIFESAVING AND LESS TOXIC TREATMENTS IN 2025, WE INVESTED IN EXCITING RESEARCH FRONTIERS, INCLUDING PRECISION MEDICINE, IMMUNOTHERAPY, AND LINKS BETWEEN MUTATIONS AND BLOOD CANCER-ADVANCEMENTS THAT ARE CHANGING THE PARADIGM OF CANCER TREATMENT. IN THE PROCESS, WE PROPELLED SEVERAL NOVEL SCIENCE INITIATIVES TO NEW HEIGHTS-MANY OF WHICH HARDLY SEEMED POSSIBLE JUST A SHORT TIME AGO.WITH ADVISORY INPUT FROM RECOGNIZED BIOMEDICAL RESEARCH EXPERTS, BLOOD CANCER UNITED FUNDED EXEMPLARY PROJECTS ACROSS THE ENTIRE RESEARCH CONTINUUM RELEVANT TO IMPROVE OUTCOMES FOR BLOOD CANCER PATIENTS, FROM BASIC LABORATORY SCIENCE THROUGH CLINICAL TRIALS, AND FROM INVESTIGATOR-INITIATED RESEARCH TO PRIVATE-SECTOR DRUG DEVELOPMENT ALLIANCES. BLOOD CANCER UNITED IS DELIBERATE AND PURPOSEFUL IN FINDING AND SUPPORTING RESEARCH THAT IS MOST LIKELY TO HELP PATIENTS AS SOON AS POSSIBLE. IN ADDITION, WHILE BLOOD CANCER UNITED DEDICATES SUBSTANTIAL FUNDING TO ADVANCING NOVEL TREATMENTS FOR BLOOD CANCER, WE RECOGNIZE THAT IT IS EQUALLY IMPORTANT THAT WE COMMIT TO IMPROVING PATIENT ACCESS TO THESE ESSENTIAL THERAPIES. TO THIS END, BLOOD CANCER UNITED ALSO SUPPORTS HEALTH SERVICES RESEARCH WORKING TO IDENTIFY BARRIERS THAT PREVENT CERTAIN PATIENTS FROM BEING ABLE TO ACCESS THE TREATMENT AND CARE THAT THEY NEED AND FINDING ACTIONABLE SOLUTIONS THAT BLOOD CANCER UNITED CAN IMPLEMENT TO OVERCOME THESE BARRIERS AND ADVANCE ITS MISSION. TO DATE, BLOOD CANCER UNITED HAS INVESTED OVER $2 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. OUR SUSTAINED RESEARCH INVESTMENT OVER MULTIPLE DECADES HAS PAID OFF HANDSOMELY. THIS IS BEST DEMONSTRATED BY OUR SEMINAL INVESTMENT IN CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR T) THERAPY STARTING IN 1990 THAT, SINCE 2017, HAS TRANSLATED INTO 18 FDA-APPROVALS FOR PEDIATRIC AND ADULT B-CELL ACUTE LEUKEMIA, FOR SEVERAL TYPES OF NON-HODGKIN LYMPHOMA, AND MULTIPLE MYELOMA. CAR T-CELL THERAPY HAS IN SOME CASES PRODUCED CURES IN PATIENTS WHO HAVE FAILED ALL OTHER THERAPEUTIC OPTIONS.IN FISCAL YEAR 2025, BLOOD CANCER UNITED SUPPORTED RESEARCH IN THE U.S., CANADA AND SEVERAL OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY $81.3 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS.EQUITY IN ACCESS RESEARCH PROGRAM IN FISCAL YEAR 2022, BLOOD CANCER UNITED LAUNCHED THE EQUITY IN ACCESS RESEARCH PROGRAM, WHICH AIMS TO FUND HEALTH SERVICES RESEARCH THAT WILL GENERATE ACTIONABLE EVIDENCE TO ASSIST BLOOD CANCER UNITED IN ADVOCATING FOR CHANGES IN HEALTHCARE POLICY, DEVELOPING PATIENT-FACING PROGRAMS, AND FOSTERING PRACTICE CHANGE TO EXTEND AND IMPROVE THE LIVES OF ALL BLOOD CANCER PATIENTS. EQUITY IN ACCESS HAS AWARDED NEARLY $18 MILLION TO RESEARCHERS ADDRESSING CRITICAL ISSUES SUCH AS THE COST OF ORAL ANTICANCER MEDICATIONS, THE ROLE OF HEALTH INSURANCE IN FINANCIAL HARDSHIP, AND ACCESS FOR EVERY PATIENT TO CLINICAL TRIALS. BLOOD CANCER UNITED RECOGNIZES THE CRITICAL NEED FOR HIGH-QUALITY EVIDENCE ON INTERVENTIONS TO INCREASE PARTICIPATION IN THERAPEUTIC CANCER CLINICAL TRIALS, WHICH ARE CONSIDERED HIGH-QUALITY CANCER CARE, PARTICULARLY AMONG UNDERREPRESENTED GROUPS (E.G., PEOPLE WHO HAVE LOW INCOMES, PEOPLE WHO LIVE IN RURAL AREAS, ETHNICALLY AND RACIALLY MINORITIZED GROUPS). IN FISCAL YEAR 2025 ALONE, EQUITY IN ACCESS AWARDED NEARLY $5 MILLION TO RESEARCHERS WHO WILL IMPLEMENT AND EVALUATE NOVEL INTERVENTION APPROACHES DESIGNED TO INCREASE THERAPEUTIC CLINICAL TRIAL ENROLLMENT. THERAPY ACCELERATION PROGRAM (TAP)TAP IS BLOOD CANCER UNITED'S MISSION-DRIVEN, STRATEGIC VENTURE PHILANTHROPY INITIATIVE THAT SEEKS TO ACCELERATE THE DEVELOPMENT OF INNOVATIVE BLOOD CANCER THERAPEUTICS AND CHANGE THE STANDARD OF CARE, WHILE ALSO GENERATING A RETURN ON INVESTMENT TO CONTINUE TO SUPPORT ITS MISSION. TAP COLLABORATES WITH BIOTECH COMPANIES TO SUPPORT THE DEVELOPMENT OF NOVEL PLATFORMS AND FIRST-IN-CLASS ASSETS ADDRESSING UNMET MEDICAL NEEDS, EMERGING PATIENT POPULATIONS AND EVEN RARE BLOOD CANCERS.ESTABLISHED IN 2007, TAP HAS INVESTED MORE THAN $115 MILLION IN OVER 50 BIOTECH COMPANY PROJECTS. SINCE 2017, FIVE TAP-SUPPORTED THERAPIES HAVE BEEN APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) OR INCLUDED IN THE NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) GUIDELINES. CURRENTLY, THERE ARE OVER 30 ACTIVE CLINICAL STUDIES WITH TAP-SUPPORTED THERAPIES, INCLUDING SEVERAL REGISTRATION-ENABLING CLINICAL STUDIES IN BLOOD CANCER THAT COULD LEAD TO MORE FDA APPROVALS.IN FISCAL YEAR 2025, TAP MADE INVESTMENTS IN FIVE BIOTECH COMPANIES THAT INCLUDED THREE EXISTING BIOTECH PARTNERS AND TWO NEW UP-AND-COMING BIOTECH COMPANIES, TO HELP THEM NAVIGATE THE DRUG DEVELOPMENT LANDSCAPE AND TO SUPPORT CLINICAL TRIALS FOR BLOOD CANCER PATIENTS. SEVERAL TAP PARTNER COMPANIES ARE BASED IN EUROPE AND NOW, WITH HELP FROM TAP, THESE COMPANIES ARE RUNNING CLINICAL TRIALS IN THE US. TAP CONTINUES TO EXPAND ITS REACH AND IMPACT BY LEVERAGING ITS UNIQUE EXPERTISE TO ATTRACT MORE COMPANIES AND INVESTORS TO BLOOD CANCER DISEASES, AND TO EXPAND THE TAP INVESTMENT CAPACITY TO SUPPORT THE MOST PROMISING ASSETS.CLINICAL TRIALSBEAT AML MASTER TRIALBEGINNING NOVEMBER 2016, BLOOD CANCER UNITED LAUNCHED THE BEAT AML MASTER TRIAL, A COLLABORATIVE CLINICAL TRIAL TESTING SEVERAL NOVEL TARGETED THERAPIES FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) DESIGNED TO FACILITATE FDA APPROVAL OF NEW DRUGS AND CHANGE THE TREATMENT PARADIGM FOR PATIENTS DIAGNOSED WITH AML BY DEVELOPING MORE INDIVIDUALIZED, EFFECTIVE TREATMENT APPROACHES. THE MASTER TRIAL INVOLVES COLLABORATIONS WITH MULTIPLE MEDICAL INSTITUTIONS, DRUG COMPANIES, A GENOMIC PROVIDER, A CLINICAL RESEARCH ORGANIZATION, AND THE FDA, ALL OF WHOM HAVE COMMITTED TO WORKING COLLABORATIVELY. IN FISCAL YEAR 2025, 135 PATIENTS ENROLLED IN A SUB-STUDY UNDER THE BEAT AML MASTER TRIAL.

  Expenses $127,080,673 · Grants $51,235,960 · Revenue $16,079,272

• B) PATIENT & COMMUNITY SERVICES:AN ESTIMATED 1.7 MILLION PEOPLE ACROSS THE UNITED STATES (US) ARE CURRENTLY LIVING WITH OR ARE IN REMISSION FROM LEUKEMIA, LYMPHOMA, MYELOMA, MYELODYSPLASTIC SYNDROMES AND MYELOPROLIFERATIVE NEOPLASMS. BLOOD CANCER UNITED OFFERS AN ARRAY OF FREE, COMPREHENSIVE RESOURCES TO BLOOD CANCER PATIENTS, CAREGIVERS, FAMILIES AND FRIENDS OFPATIENTS, ADVOCATES, HEALTHCARE PROFESSIONALS AND THE PUBLIC. BLOOD CANCER UNITED IS COMMITTED TO PROVIDING THE MOST ACCURATE AND UP-TO-DATE BLOOD CANCER INFORMATION. PROFESSIONAL VOLUNTEER CLINICAL ADVISORS WORK WITH BLOOD CANCER UNITED STAFF TO REVIEW ALL OF THE INFORMATION BLOOD CANCER UNITED PROVIDES THROUGH HEALTHCARE PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE BLOOD CANCER UNITED WEBSITE. SUPPORT SERVICES ARE PROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE-TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS.FINANCIAL ASSISTANCE OUR FINANCIAL ASSISTANCE PROGRAMS AIM TO LESSEN THE ECONOMIC TOLL ON PATIENTS AND FAMILIES TO HELP PATIENTS AFFORD LIFE-SAVING TREATMENTS. TO COUNTER CONTINUALLY RISING DRUG PRICES AND ALLEVIATE THE BURDENS FELT BY PATIENTS COPING WITH BLOOD CANCER, BLOOD CANCER UNITED PROVIDED 69,120 GRANTS TOTALING OVER $162M IN ASSISTANCE AWARDED. THE MAJORITY, $153M, SUPPORTED PATIENTS' INSURANCE PREMIUMS, TREATMENT-RELATED CO-PAYS, AND CO-INSURANCE OUT OF POCKET COSTS THROUGH OUR CO-PAY ASSISTANCE PROGRAM. IN KEEPING WITH OUR COMMITMENT TO DIVERSITY, EQUITY, AND INCLUSION, BLOOD CANCER UNITED RECOGNIZES THAT NEED EXISTS THROUGHOUT ALL GEOGRAPHIC REGIONS AND WITHIN ALL PATIENT POPULATIONS, INCLUDING THOSE TRADITIONALLY UNDERREPRESENTED. CO-PAY ASSISTANCE PROGRAM THE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO-PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH BLOOD CANCER UNITED TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2025, BLOOD CANCER UNITED AWARDED 35,302 GRANTS THROUGH ITS CO-PAY ASSISTANCE PROGRAM. SUSAN LANG PRE CAR T-CELL THERAPY TRAVEL ASSISTANCE PROGRAM BLOOD CANCER UNITED AWARDED 270 GRANTS EACH IN THE AMOUNT OF $2,500 FOR TREATMENT-RELATED TRANSPORTATION AND LODGING COSTS FOR PATIENTS WHO ARE BEING EVALUATED TO RECEIVE CAR T-CELL THERAPY AS EITHER STANDARD TREATMENT OR A CLINICAL TRIAL. SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM BLOOD CANCER UNITED AWARDED 2,040 GRANTS EACH IN THE AMOUNT OF $500 FOR TREATMENT-RELATED TRANSPORTATION AND LODGING COSTS. URGENT NEED PROGRAM IN PARTNERSHIP WITH MOPPIE'S LOVE AND CHARLIE'S FUND, BLOOD CANCER UNITED AWARDED 9,119 GRANTS EACH IN THE AMOUNT OF $500 FOR NON-MEDICAL LIVING EXPENSES-INCLUDING RENT, UTILITIES, AND FOOD. LOCAL FINANCIAL ASSISTANCE PROGRAM BLOOD CANCER UNITED AWARDED 989 GRANTS EACH IN THE AMOUNT OF $500 TO COVER NON-MEDICAL LIVING EXPENSES-INCLUDING RENT, UTILITIES, AND FOOD, ETC.PATIENT AID PROGRAM BLOOD CANCER UNITED AWARDED ONE-TIME STIPENDS OF $100 TO OVER 20,345 PATIENTS TO HELP OFFSET NON-MEDICAL EXPENSES. PATIENT AID HELENE & MILTON BLOOD CANCER UNITED AWARDED ONE-TIME STIPENDS OF $100 TO 1055 PATIENTS WHO RESIDED IN DESIGNATED ZIP CODES DECLARED FOR INDIVIDUALASSISTANCE BY FEMA, TO ALLEVIATE FINANCIAL HARDSHIP AS A RESULT OF THE HURRICANES. MEDICAL DEBT CASE MANAGEMENT PROGRAM BLOOD CANCER UNITED'S MEDICAL DEBT CASE MANAGEMENT PROGRAM PROVIDES ONE-ON-ONE, PERSONALIZED SUPPORT TO EMPOWER PATIENTS TO ADDRESS THEIR MEDICAL DEBT IN THE FOLLOWING WAYS: ADDRESS FINANCIAL CONCERNS, INCLUDING MANAGING EXISTING MEDICAL DEBT AND PLANNING FOR UPCOMING MEDICAL EXPENSES; IDENTIFY RESOURCES SUCH AS CHARITY CARE ORGANIZATIONS OR MANUFACTURER PATIENT ASSISTANCE PROGRAMS THAT MAY REDUCE THE FINANCIAL BURDEN; ASSIST WITH INSURANCE PLAN EVALUATION AND ENROLLMENT, SUCH AS MEDICAID, MEDICARE, MARKETPLACE PLANS, AND EMPLOYER-SPONSORED HEALTH INSURANCE; NAVIGATE INSURANCE BENEFITS, DENIALS OF CARE, AND OUT-OF-POCKET COSTS; AND PROVIDE SUPPORT WITH CHARITY CARE, NEGOTIATIONS, INVOICE REVIEW, ETC. THE MEDICAL DEBT CASE MANAGEMENT PROGRAM HANDLED 1579 CASES, HELPING IN THE RESOLUTION OF $3.8 MILLION IN MEDICAL DEBT BLOOD CANCER UNITED IS NOT A DEBT FORGIVENESS PROGRAM, DOES NOT PAY OFF MEDICAL DEBT, AND CANNOT ASSIST WITH DEBT THAT IS IN COLLECTIONS. PROGRAM CASE MANAGERS WORK WITH PATIENTS AND OFFER WAYS TO HELP MANAGE CURRENT DEBT AND PREVENT ACCUMULATING MORE. SCHOLARSHIP FOR BLOOD CANCER SURVIVORS IN 2025, THE BLOOD CANCER UNITED SCHOLARSHIP FOR BLOOD CANCER SURVIVORS AWARDED 285 SCHOLARSHIPS EACH UP TO $7,500 IN TUITION SUPPORT FOR VIRTUAL OR IN-PERSON VOCATIONAL, TWO-YEAR, OR FOUR-YEAR UNDERGRADUATE EDUCATION.

  Expenses $123,558,480 · Grants $72,847,874

• C) PUBLIC HEALTH EDUCATION: BLOOD CANCER UNITED BELIEVES KNOWLEDGE IS POWER. AS ALWAYS, BLOOD CANCER UNITED HAS OFFERED THEIR INFORMATIONAL PROGRAMS IN VIRTUAL FORMATS, CONTINUING TO PROVIDE VITALLY NEEDED EDUCATION AND EMOTIONAL SUPPORT FOR THOSE IMPACTED BY BLOOD CANCER. ONE-ON-ONE EDUCATION AND SUPPORTTRAINED ONCOLOGY INFORMATION SPECIALISTS IN OUR INFORMATION RESOURCE CENTER (IRC) PROVIDE PATIENTS AND CAREGIVERS WITH COMPASSIONATE, COMPREHENSIVE, AND TAILORED DISEASE AND TREATMENT INFORMATION, INCLUDING REFERRALS AND LINKS TO APPROPRIATE EDUCATIONAL RESOURCES AND LITERATURE; PSYCHOSOCIAL SUPPORT INFORMATION FOR ANY POINT IN THEIR TREATMENT JOURNEY; REFERRALS TO RELEVANT LOCAL, STATE AND/OR NATIONAL RESOURCES FOR ASSISTANCE; COVID-19 RELATED INFORMATION AND GUIDANCE; AND FINANCIAL RESOURCE INFORMATION TO COVER COSTS OF TREATMENT, TRAVEL, URGENT NEEDS AND MORE. OVER 28,000 INTERACTIONS BETWEEN THE IRC AND PATIENTS AND CAREGIVERS TOOK PLACE LAST YEAR.FACILITATING CLINICAL TRIAL ACCESSTHE BLOOD CANCER UNITED CLINICAL TRIAL SUPPORT CENTER (CTSC) CONTINUES TO EXPAND THE POSSIBILITY OF POSITIVE OUTCOMES FOR PATIENTS BY PROVIDING EDUCATION, IDENTIFYING SUITABLE CLINICAL TRIALS, AND ADDRESSING BARRIERS TO ENROLLMENT. OUR CLINICAL TRIAL NURSE NAVIGATORS ASSISTED 1158 PATIENTS AND TWENTY PERCENT OF THESE PATIENTS ENTERED A TRIAL.OUTREACH TO UNDERSERVED GROUPSWE AUGMENTED EFFORTS TO EXPAND ACCESS TO BLOOD CANCER UNITED SERVICES AND RESOURCES BY BOLSTERING RELATIONS WITH COMMUNITY GROUPS AND LEADERS, NOTABLY IN THE BLACK AND LATINO COMMUNITIES, AND INCREASED OUR NUMBER OF BILINGUAL STAFF AND VOLUNTEERS. WE ALSO INCREASED ACCESSIBILITY OF OUR EDUCATION PROGRAMS TO RURAL PATIENTS AND FAMILIES VIA OUR VIRTUAL OFFERINGS.MOREOVER, WE CONTINUED TO EXPAND PARTNERSHIPS WITH AFFINITY GROUPS, INCLUDING NATIONAL MINORITY QUALITY FORUM, NATIONAL ASSOCIATION OF RURAL HEALTH, HAIRY CELL LEUKEMIA FOUNDATION, THE BALM IN GILEAD, LATINO MEDICAL STUDENTS ASSOCIATION, IN ADDITION TO MAINTAINING RELATIONSHIPS WITH THOSE GROUPS WITH WHICH WE WERE PREVIOUSLY CONNECTED. THE BLOOD CANCER UNITED MYELOMA LINK PROGRAM, LAUNCHED IN FISCAL YEAR 2017, CONTINUED TO GAIN TRACTION.WE IMPROVED UNDERSTANDING OF TREATMENT OPTIONS BY PROVIDING IMPORTANT INFORMATION TO AFRICAN AMERICANS, WHO ARE TWICE AS LIKELY TO BE DIAGNOSED WITH MULTIPLE MYELOMA AS CAUCASIAN AMERICANS. IN FISCAL YEAR 2025, BLOOD CANCER UNITED REACHED NEARLY 21,000 PEOPLE THROUGH MYELOMA LINK NATIONAL AND REGIONAL EDUCATION AND OUTREACH ACTIVITIES IN 18 CITIES ACROSS THE U.S.IN 2025, BLOOD CANCER UNITED REACHED OVER 20,000 SPANISH-SPEAKING INDIVIDUALS NATIONWIDE THROUGH HEALTHCARE PROFESSIONAL OUTREACH, LOCAL HEALTH FAIRS, COMMUNITY EVENTS, AND OTHER GRASSROOTS ACTIVITIES. OUR NATIONAL SPANISH-LANGUAGE FACEBOOK LIVE SEGMENTS, COVERING TOPICS SUCH AS NUTRITION, MENTAL HEALTH, AND PATIENTS' RIGHTS, GARNERED OVER 1 MILLION VIEWS. WE STRENGTHENED OUR OUTREACH STRATEGY IN PUERTO RICO THROUGH EXPANDED PATIENT REFERRAL COLLABORATIONS, DEEPER HEALTHCARE PROVIDER ENGAGEMENT, AND TARGETED MEDIA PARTNERSHIPS. HIGHLIGHTS INCLUDED IMPROVING REFERRAL PROCESSES WITH MAJOR HOSPITALS, COORDINATING CO-BRANDED EDUCATION WITH THE AMERICAN CANCER SOCIETY, AND PARTNERING WITH BEHEALTHPR TO BROADEN REACH AMONG SPANISH-SPEAKING AUDIENCES. THESE EFFORTS ARE CRITICAL TO ADDRESSING SYSTEMIC ACCESS BARRIERS AND ENSURING EQUITABLE DELIVERY OF INFORMATION, NAVIGATION, AND SUPPORT SERVICES ACROSS THE ISLAND.EDUCATION AND PATIENT CONNECTIONS.OUR VIRTUAL EDUCATION PROGRAMS PROVIDED BOTH PATIENTS AND FAMILIES, AS WELL AS HEALTH CARE PROFESSIONALS, ACCESS TO CONTENT INCLUDING BLOOD CANCER CONFERENCES, LOCAL EDUCATION PROGRAMS, NATIONAL WEBINARS, VIDEOS, LECTURES, AND PODCASTS. BLOOD CANCER UNITED'S HIGHLY VIEWED WEBSITE CONTINUES TO PROVIDE THE MOST UP TO DATE BLOOD CANCER INFORMATION INCLUDING ACCESS TO BLOGS, BOOKLETS, WORKBOOKS, FACT SHEETS AND MORE. IN ADDITION, 1,754 CANCER PATIENTS WERE PROVIDED WITH PERSONALIZED NUTRITION CONSULTATIONS BY BLOOD CANCER UNITED'S REGISTERED DIETITIANS. OUR PATIENT & COMMUNITY OUTREACH TEAM CONTINUED TO BRING PATIENTS TOGETHER VIA ONLINE LOCAL SUPPORT GROUPS AND CHATS. THE PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM MATCHED 2,065 PATIENTS WITH TRAINED VOLUNTEERS WHO PROVIDE UNDERSTANDING AND SUPPORT. IN ADDITION, MEMBERSHIP IN THE BLOOD CANCER UNITED COMMUNITY - OUR ONLINE SOCIAL NETWORK - WAS 24,239, AN INCREASE OF 6% OVER FISCAL YEAR 2024.

  Expenses $28,509,773

• BLOOD CANCER UNITED SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. VARYING FORMATS ARE OFFERED TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. UPCOMING AND ARCHIVED CE/CME PROGRAMS ARE AVAILABLE AT HTTPS://BLOODCANCERUNITED.ORG/RESOURCES/HEALTHCARE-PROFESSIONALSIN FY 2025:-BLOOD CANCER UNITED PROVIDED 22 CME/CE-GRANTING LIVE EDUCATIONAL PROGRAMS, WITH 2,266 HEALTHCARE PROFESSIONALS IN ATTENDANCE. IN ADDITION, 48 VIRTUAL LECTURES WERE PRESENTED WITH OVER 66,000 PARTICIPANTS.- OVER 33,000 PATIENTS AND PROFESSIONALS PARTICIPATED IN LIVE EDUCATION PROGRAMS DELIVERED VIRTUALLY AS WELL AS DELIVERED IN PERSON, LOCALLY AND REGIONALLY.--THERE WERE OVER 214,000 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS, VIRTUAL LECTURES AND VIDEOS AND OVER 75,500 PODCAST DOWNLOADS. OVER 856,000 BOOKLETS AND FACT SHEETS WERE EITHER DOWNLOADED OR ORDERED IN HARD COPY.

  Expenses $16,653,111

As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

• DANA-FARBER CANCER INSTITUTE INC

  $5,197,687

  RESEARCH GRANT

• THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

  $2,518,448

  RESEARCH GRANT

• SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH

  $2,513,800

  RESEARCH GRANT

• THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

  $2,257,440

  RESEARCH GRANT

• WASHINGTON UNIVERSITY IN ST LOUIS

  $2,252,023

  RESEARCH GRANT

• JOAN & SANFORD I WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY

  $2,115,000

  RESEARCH GRANT

• UNIVERSITY OF FLORIDA

  $2,009,874

  RESEARCH GRANT

• UNIVERSITY OF COLORADO DENVER ANSCHUTZ MEDICAL CAMPUS

  $1,966,500

  RESEARCH GRANT

• EMORY UNIVERSITY

  $1,661,071

  RESEARCH GRANT

• FRED HUTCHINSON CANCER CENTER

  $1,550,000

  RESEARCH GRANT

The 10 largest by cash amount. The API serves every itemized grant.

Related organizations on this return

Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.

• THE LLS OF CANADA

  BLOOD CANCER RESERACH · CA

• BLOOD CANCER UNITED RESEARCH FOUNDATION

  501(C)(3) · SUPPORTS BLOOD CANCER UNITED · DE · controlled entity

  Directly controlled by BLOOD CANCER UNITED INC

• BLOOD CANCER UNITED RESEARCH PROGRAMS INC

  501(C)(3) · SUPPORTS BLOOD CANCER UNITED · DE · controlled entity

  Directly controlled by BLOOD CANCER UNITED INC

Taxable family on this return

Schedule R Parts I, III and IV, as filed. These record ownership and control, not shared board members or money moved.

Provenance

Return type

form_990

Tax year

2024

Filed

26 February 2026

IRS schema version

2024v5.5

Source object

202620589349300007

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.